Figure S5. Tandem GRM1 Mutations Identified by Exome Sequencing
Left panel: Integrative Genomics Viewer snapshot of the short reads alignment from the exome sequencing of family V. The 3bp c.2652_2654del deletion is shown as a gap, the c.2660+2T>G mutation, is in orange, boxed. Nucleotide positions follow the hg19 reference genome. Right panel: Verification of the mutations by Sanger sequencing. PCR amplification and sequencing were done with primers 5'-ACTATGCCTTCAAGACCCGC-3' and 5'-GGGGAAATGGAAGAGACAAC-3'. On the chromatograms, c.2652_2654del is boxed in the wild-type and its position indicated with an arrow in the mutant sequence; c.2660+2T>G is highlighted. In heterozygotes, c.2652_2654del is unambiguously detected, while c.2660+2T>G is masked on the forward strand (shown) by the deletion, and on the reverse strand by an intronic repeat starting 20 bp downstream. Its presence was confirmed by pyrosequencing (Suplemental Figure S7) .
Figure S7. Pyrosequencing as a Confirmatory Test for the Presence of the Mutations
Pyrograms of A) unaffected control, B) heterozygote carrier and C) ataxia patient. Peak heights are shown as relative light units detected for nucleotide dispensed. The heights at variable sites are compared to those generated by surrounding known sequence to determine the sequence at the variable site. At the c.2652_2654del mutation site, the height of the G and A peaks decreases in mutation heterozygotes and further in homozygotes. For the c.2660+2T>G mutation, heterozygosity and homozygosity for the mutant G allele results in increasing peak height, representing a sequence of three consecutive Gs at dispense 10.
A 258 base pair segment containing the mutated sites was PCR amplified (primers and conditions in the table below). A biotin-labeled primer (IDT) was used to purify the final PCR product using Sepharose beads. The PCR product was bound to Streptavidin Sepharose High Performance beads (GE Healthcare Life Sciences, Rydalmere, NSW, Australia), and the sepharose beads containing the immobilized PCR product were denatured, and washed using proprietary solutions (Qiagen, Doncaster, Vic, Australia) on the Pyrosequencing Vacuum Prep Tool (Qiagen). 0.3 µM of pyrosequencing primer was annealed to the purified singlestranded PCR product. Pyrosequencing was performed on a PyroMark 24 Pyrosequencing System (Qiagen). Data analysis was performed using the PyroMark Q24 software.
Pyrosequencing primers Primer name

Sequence
Modification/purification GRM1_F GTG CCT TCA CCA CCT CTG ATG Standard Desalting GRM1_R /5Biosg/GGG GAA ATG GAA GAG ACA ACT 5' Biotin/ HPLC Purification GRM1_S AGA AGG CAG GGG CAG Standard Desalting
Figure S8. GRM1 Expression Levels in Control and Ataxia LCLs
Left panel: Agarose gel electrophoresis of RT-PCR products obtained with primers targeting invariable upstream exons3-4 (expected fragment size 304bp). Right panel: GRM1 transcript abundance relative to endogenous SDHA expression. 1 Standards (3 to 300,000 copies) were prepared by serial dilutions of the RT-PCR products from normal LCLs, after concentration measurements with the Quant-iT PicoGreen dsDNA kit (Life Technologies, Mulgrave, Vic, Australia) and product size conversions to the mass of a single copy. 2 Quantitative PCR (in triplicates), was done with iQ SYBR Green Supermix (BioRad, Gladesville, NSW, Australia). Standard curves were generated by plotting the average Ct values versus the logtransformed input copies of the standards (R 2 >0.99). The number of copies in test samples was interpolated using the linear regression formula.
Figure S9. Control PCR Testing for Genomic DNA Contamination of the RNA Samples Used in the RT-PCR Amplifications
The forward primer is in GRM1 exon 7, the reverse primer is in intron 7, and the expected product for gDNA is 231 bp (Table S4 ).
S10. mGluR1α and mGluR1β1 Protein Domains and Predicted Products of the Aberrant Transcripts Observed in Ataxia LCLs
The receptor domains and corresponding numbers of constituent amino acid (AA) in the nomal mGluR1α and mGluR1β1 isoforms are as shown in UniProt Accession number Q13255. Predictions of the products of experimentally observed aberrant transcrips were obtained using the Expasy Translate Tool. Different colours are used to highlight differences in the intracellular tail, with a small number of AA residues shown in the critical regions affected by the mutation. The vertical line in the tail delineates the parts encoded by exon 8 and downstream exons. Exon 8 skipping is predicted to lead to receptor molecules missing the conserved transmembrane domain. In addition, exon 8 (931bp) skipping will shift the exon 10 reading frame, substituting 30 different AA for the 354 AA tail of the normal "long" mGluR1α isoform. The normal "short" mGluR1 β1 isoform will be replaced by a hybrid molecule, where 28 different AA are encoded by exon 9, the reading frame is restored and the 308 AA encoded by exon 10 are added. Transcripts ending in intron 8 are predicted to encode a truncated protein, where the RRKK amino acid sequence is exposed. LBDligand-binding domain; CRD -cysteine-rich domain; 7TM -7 transmembrane domain. Ins -insertion; Fsh -frame shift; w -weeks; BAEPs -brainstem auditory evoked potentials; Ref -reference Reverse transcription (RT)-PCR Lymphoblastoid cell lines (LCLs) were established using standard protocols for EBV transformation and culture conditions (37°C/5%CO 2 in advanced RPMI, supplemented with Glutamax, 20% foetal calf serum and 100U/ml Penicillin/Streptomycin). Total RNA was extracted using RNeasy Plus Mini kit from ~6X10 6 cells homogenized with QIAshredder columns and treated with RNAse-Free DNAse (reagents from QIAGEN, Doncaster, Vic, Australia). Four µg total RNA per sample were used for cDNA synthesis by the SuperScript III First-Strand Synthesis System (Life Technologies, Mulgrave, Vic, Australia).
Positive controls included HeLa total RNA (provided with the kit) and human brain total RNA (Clontech, Mountain View, CA, USA), and RNAse-free water served as a negative control. Prior to PCR, cDNA products were diluted 1:10 in nuclease-free water (1:100 for brain cDNA). GRM1 RT-PCR was carried out in 24 µl reactions, containing 4 µl cDNA, 0.6 µM primers, 5% DMSO, and 1X KAPA Taq ReadyMix (Kapa Biosystems, Woburn, CA, USA). Reaction conditions were as described, 40 (main text ) with initial denaturation at 95°C for 2 min, 10 cycles of denaturation at 94°C for 20 sec, annealing at 64°C for 15 sec with a touch down 0.5°C/cycle, and extension at 72°C for 1 min, 44 cycles of denaturation at 94°C for 20 sec, annealing at 59°C for 15 sec, and extension at 72°C for 1 min, and final extension at 72°C for 5 min. 
